XNVA Xenova Grp. Plc ADS (MM)

Webcast Alert: Xenova Group PLC Announces Its R & D Breakfast Webcast NEW YORK, June 28 /PRNewswire/ -- Xenova Group plc (LONDON: XEN) announces the following Webcast: What: Xenova Group PLC R & D Breakfast Webcast When: June 29, 2004 @ 08:30 AM Eastern Where: http://www.vcall.com/EventPage.asp?ID=88448 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Lee Stern, 212-477-9007 or If you are unable to participate during the live webcast, the call will be available for replay at http://www.vcall.com/ClientPage.asp?ID=88448 or http://www.vcall.com/ Xenova Group plc is a UK-based biopharmaceutical company focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. The Company has a broad pipeline of products in clinical development, including three cancer programmes: its lead product TransMIDTM, for the treatment of high-grade glioma, is in Phase III trials, and its novel DNA targeting agents and XR303 are both in Phase I for cancer indications. Xenova is also developing two therapeutic vaccines for cocaine and nicotine addiction, which are in Phase II and Phase I trials respectively. Quoted on the London Stock Exchange (XEN) and on (NASDAQ:XNVA), Xenova employs approximately 112 people throughout its sites in the UK and North America. (Reuters XEN.L; Bloomberg XEN LN) For further information about Xenova and its products please visit the Xenova website at http://www.xenova.co.uk/. DATASOURCE: Xenova Group plc CONTACT: Lee Stern, +1-212-477-9007, or , for Xenova Group plc Web site: http://www.xenova.co.uk/ http://www.vcall.com/EventPage.asp?ID=88448

Copyright